Statement of Changes in Beneficial Ownership (4)
June 08 2020 - 7:34PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Sofinnova Capital VII FCPR |
2. Issuer Name and Ticker or Trading Symbol
Shockwave Medical, Inc.
[
SWAV
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/4/2020 |
(Street)
SANTA CLARA, CA 95054
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 6/4/2020 | | S | | 4000 | D | $45.03 (2) | 3120800 | D (1) | |
Common Stock | 6/5/2020 | | S | | 55754 | D | $45.04 (3) | 3065046 | D (1) | |
Common Stock | 6/8/2020 | | S | | 59879 | D | $45.11 (4) | 3005167 | D (1) | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Shares held by the reporting person are also reported on Form 4 by Antoine Papiernik, one of the managing partners of Sofinnova Partners SAS, a French corporation and the management company of the reporting person. Mr. Papiernik disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest. |
(2) | The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $45.00 to $45.15. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
(3) | The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $45.00 to $45.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
(4) | The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $45.00 to $45.48. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
Remarks: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/06/2019. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Sofinnova Capital VII FCPR C/O SHOCKWAVE MEDICAL, INC. 5403 BETSY ROSS DRIVE SANTA CLARA, CA 95054 |
| X |
|
|
Signatures
|
/s/ Trinh Phung, as attorney-in-fact for Sofinnova Capital VII FCPR | | 6/8/2020 |
**Signature of Reporting Person | Date |
Shockwave Medical (NASDAQ:SWAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shockwave Medical (NASDAQ:SWAV)
Historical Stock Chart
From Apr 2023 to Apr 2024